
Nivolumab Plus Ipilimumab Improves HRQOL Vs Nivolumab Alone in MSI-H/dMMR mCRC
The addition of ipilimumab (Yervoy) to nivolumab (Opdivo) not only led to a significant improvement in progression-free survival (PFS) over nivolumab alone, but it also resulted in better health-related quality of life (HRQOL) and reduced symptoms in …